Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Impressive H1 from Oxford Nanopore should allay investor concerns, says Berenberg

(Sharecast News) - Shares in Oxford Nanopore Technologies surged on Monday after the molecular tech group updated the market on a strong first-half performance, something which broker Berenberg says has "de-risked" the delivery of full-year guidance. Berenberg kept a 'buy' rating and 250p target price for the stock, which was up nearly 20% at 175.79p by 0937 BST.

ONT, which makes nanopore sequencing products, said in an update ahead of its interim results on 2 September that revenues are expected to be up 28% year-on-year at £105m, some 5% ahead of company-compiled consensus.

Despite the first-half beat, the company left full-year guidance unchanged, given tougher comparatives in the second half.

"However, we think that the performance in H1 somewhat de-risks delivery on full-year guidance and should allay some investor concerns regarding the macro uncertainties in the company's endmarkets, most notably in the US," the broker said.

Berenberg noted the "good progress" made by ONT across all end-markets and geographies, which makes it confident that the company will deliver on its full-year revenue guidance of 20-23% growth at constant currencies.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.